Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Multiple Myeloma (RRMM)”

143 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 143 results

Testing effectiveness (Phase 2)WithdrawnNCT03221634
What this trial is testing

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Who this might be right for
Multiple Myeloma
Merck Sharp & Dohme LLC
Not applicableLooking for participantsNCT06961669
What this trial is testing

Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

Who this might be right for
Lymphoblastic LeukemiaRelapsed or Refractory Multiple Myeloma (RRMM)
Anhui Provincial Hospital 18
Very early researchNot Yet RecruitingNCT07322159
What this trial is testing

IASO206 in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)
Institute of Hematology & Blood Diseases Hospital, China 12
Not applicableLooking for participantsNCT07497165
What this trial is testing

Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma (RRMM)Multiple Myeloma
Shanxi Bethune Hospital 48
Early research (Phase 1)WithdrawnNCT05918250
What this trial is testing

MRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.
Early research (Phase 1)UnknownNCT04677452
What this trial is testing

Dose Exploration Study OF JWCAR129, BCMA-Targeted CART for RRMM

Who this might be right for
Safety and Efficacy
The First Affiliated Hospital of Soochow University 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT05704049
What this trial is testing

Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Sanofi 118
Early research (Phase 1)UnknownNCT05698303
What this trial is testing

Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Nanjing IASO Biotechnology Co., Ltd. 12
Testing effectiveness (Phase 2)Temporarily pausedNCT06876142
What this trial is testing

Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaRelapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI) 54
Early research (Phase 1)Looking for participantsNCT03110822
What this trial is testing

Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Who this might be right for
Multiple Myeloma
Oncotherapeutics 134
Early research (Phase 1)Looking for participantsNCT06622005
What this trial is testing

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Roswell Park Cancer Institute 15
Testing effectiveness (Phase 2)Ended earlyNCT06160609
What this trial is testing

Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM

Who this might be right for
Relapsed/Refractory Multiple Myeloma
GlaxoSmithKline 9
Testing effectiveness (Phase 2)Study completedNCT04191616
What this trial is testing

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Amgen 54
Testing effectiveness (Phase 2)Looking for participantsNCT07116616
What this trial is testing

MRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc. 166
Testing effectiveness (Phase 2)Ended earlyNCT02807454
What this trial is testing

Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene 37
Early research (Phase 1)Active Not RecruitingNCT04398745
What this trial is testing

Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 36
Testing effectiveness (Phase 2)Looking for participantsNCT07382739
What this trial is testing

Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

Who this might be right for
Phase 2Radiotherapy-Induced Immune PrimingElranatamab+4 more
M.D. Anderson Cancer Center 34
Early research (Phase 1)Active Not RecruitingNCT05286229
What this trial is testing

Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan

Who this might be right for
Relapsed/Refractory Multiple Myeloma
AbbVie 8
Very early researchActive Not RecruitingNCT05838131
What this trial is testing

Study of CT071 Injection in RRMM or PPCL

Who this might be right for
Multiple MyelomaPrimary Plasma Cell Leukemia
Shanghai Changzheng Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06356571
What this trial is testing

Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Plasma Cell Myeloma Refractory
Sanofi 64
Load More Results